| Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience |
28 |
| Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads |
28 |
| Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma |
23 |
| Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis |
22 |
| Radiomics to predict immunotherapy-induced pneumonitis: proof of concept |
19 |
| Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors |
18 |
| Emerging roles of non-coding RNAs in the pathogenesis, diagnosis and prognosis of osteosarcoma |
18 |
| Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment |
15 |
| Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma |
14 |
| Lopinavir-NO, a nitric oxide-releasing HIV protease inhibitor, suppresses the growth of melanoma cells in vitro and in vivo |
13 |
| Ruxolitinib plus capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies |
13 |
| A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors |
12 |
| Pre-clinical effects of metformin and aspirin on the cell lines of different breast cancer subtypes |
12 |
| A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012-12 (EDALINE) study |
11 |
| LEF1-AS1 contributes to proliferation and invasion through regulating miR-544a/FOXP1 axis in lung cancer |
11 |
| Phase II study of avelumab in multiple relapsed/refractory germ cell cancer |
11 |
| A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors |
10 |
| Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors |
10 |
| A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer |
10 |
| First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile |
9 |
| A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma |
9 |
| Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer |
9 |
| A phase dose-escalation study of PF-0666 an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors |
9 |
| Safety, tolerability, and pharmacology of AB a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers |
9 |
| Cyclodextrin polymers as nanocarriers for sorafenib |
9 |
| E an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases |
8 |
| Relationship between expression of XRCC1 and tumor proliferation, migration, invasion, and angiogenesis in glioma |
8 |
| Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer |
8 |
| Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer |
7 |
| A phase Ib study of BGJ a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor |
7 |
| Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2 |
7 |
| Inhibition of SHP2 by new compounds induces differential effects on RAS/RAF/ERK and PI3K/AKT pathways in different cancer cell types |
7 |
| A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors |
7 |
| Vinblastine and antihelmintic mebendazole potentiate temozolomide in resistant gliomas |
7 |
| Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001) |
7 |
| Discovery and anticancer evaluation of a formononetin derivative against gastric cancer SGC7901 cells |
7 |
| Safety, tolerability, and preliminary activity of IMGN a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study |
7 |
| A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event |
7 |
| An orally antitumor chalcone hybrid inhibited HepG2 cells growth and migration as the tubulin binding agent |
7 |
| Safety and efficacy of immune checkpoint inhibitors for end-stage renal disease patients undergoing dialysis: a retrospective case series and literature review |
7 |
| The Monocarboxylate transporter inhibitor Quercetin induces intracellular acidification in a mouse model of Glioblastoma Multiforme: in-vivo detection using magnetic resonance imaging |
6 |
| MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping |
6 |
| A phase I study of the safety and tolerability of VLX an Iron Chelator, in patients with refractory advanced solid tumors |
6 |
| A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma |
6 |
| Increased DKC1 expression in glioma and its significance in tumor cell proliferation, migration and invasion |
6 |
| CUDC- a dual HDAC and PI3K inhibitor, reverses platinum drug resistance |
6 |
| A phase I trial to determine safety and pharmacokinetics of ASLAN an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers |
6 |
| Phase I dose escalation study of NMS-128 an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors |
6 |
| The rhenium(I)-diselenoether anticancer drug targets ROS, TGF-beta VEGF-A, and IGF-1 in an in vitro experimental model of triple-negative breast cancers |
6 |
| A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer |
6 |
